On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy. Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Responses. One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and h…